| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 37 |
| 1 | NIVOLUMAB | 29 |
| 2 | CARBOPLATIN | 12 |
| 3 | IPILIMUMAB | 12 |
| 4 | PEMETREXED DISODIUM | 9 |
| 5 | PEMETREXED | 8 |
| 6 | OXALIPLATIN | 5 |
| 7 | DEXAMETHASONE | 4 |
| 8 | DEXAMETHASONE 1.5 MG | 4 |
| 9 | LENVATINIB | 4 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NALDEMEDINE | 2 | 0.0012 |
| 1 | TREMELIMUMAB | 2 | 0.0005 |
| 2 | PEMBROLIZUMAB | 37 | 0.0003 |
| 3 | AZILSARTAN KAMEDOXOMIL | 1 | 0.0003 |
| 4 | LEVOLEUCOVORIN INJECTION | 1 | 0.0003 |
| 5 | NIVOLUMAB | 29 | 0.0003 |
| 6 | IPILIMUMAB | 12 | 0.0003 |
| 7 | LEVOLEUCOVORIN | 1 | 0.0003 |
| 8 | AVELUMAB | 1 | 0.0002 |
| 9 | PEMETREXED DISODIUM | 9 | 0.0002 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 66 | 0.0007 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 14 | 0.0003 |
| 2 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 1 | 0.0002 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 3 | 0.0001 |
| 4 | Platinum-based Drug [EPC] | 17 | 0.0001 |
| 5 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 1 | 0.0000 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 8 | 0.0000 |
| 7 | Microtubule Inhibitor [EPC] | 3 | 0.0000 |
| 8 | Xanthine Oxidase Inhibitor [EPC] | 3 | 0.0000 |
| 9 | Azole Antifungal [EPC] | 2 | 0.0000 |